TABLE 2

Outcomes Pre- and Post-pathway Implementation Among Pathway-Eligible Patients

Outcome MeasurePre-implementationPost-implementationDifference (95% CI)P
IVF infusion, h, median18.018.0.19
IVF composition usage, n (%)
 Isotonic (NS)560 (9.3)2819 (50.6)41.3 (39.8 to 42.8)<.001
 Hypotonic (any)5679 (94.2)3155 (56.6)−37.6 (−39.0 to −36.2)<.001
 1/2 NS5494 (91.1)3145 (56.4)−34.7 (−36.1 to −33.2)<.001
 1/4 NS264 (4.4)15 (0.3)−4.1 (−4.7 to −3.6)<.001
ED IVF encounters with K-containing IVF, n (%)965 (52.9)1204 (75.3)22.5 (19.4 to 25.6)<.001
Eligible patients with sodium level check, n (%)362 (18.4)537 (30.5)12.1 (9.4 to 14.8)<.001
% of eligible d with wt collected, mean (SD)47.9 (43.5)55.6 (42.9)7.8 (4.8 to 10.7)<.001
Instances of dysnatremia24
Total costs (2016 $), mean (SD)18879.8 (21002.1)19580.6 (20789.9)700.8 (−108.0 to 1409.1).07
Fluid costs (2016 $), mean (SD)99.5 (106.4)113.6 (121.4)14.1 (10.1 to 18.1)<.001
Electrolyte laboratory test costs (2016 $), mean (SD)62.0 (86.1)58.6 (71.8)−3.4 (−8.1 to 2.0).20
Serum sodium laboratory test costs (2016 $), mean (SD)15.9 (9.1)15.6 (6.8)−0.3 (−3.3 to 2.3).85
  • Differences represent differences in rates where rates are shown. Otherwise, it is the difference in means. Differences, 95% CIs, and P values are estimated using t tests or rank-sum tests for comparison of medians. K, potassium; —, not applicable.